A Study of LY4515100 in Healthy Participants

← catalyst calendar

NCT07339722 · readout ≤ 224 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Basic science

Enrollment

123estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-01-15

actual

When the study began enrolling

Primary completion

Mar 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2027

estimated

The whole study's end, after follow-up

First posted

2026-01-14

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy

Interventions

Drug: LY4515100 via SAD
Drug: LY4515100 via MAD
Drug: LY4515100
Drug: Itraconazole
Drug: Caffeine
Drug: Digoxin
Drug: Iohexol
Drug: Metformin
Drug: Rosuvastatin
Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF

Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and B

measured Day 1 up to Day 30

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed